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Background: Stem cells have shown promising potential to treat burn wounds. 
Erythropoietin was capable of promoting in vitro transdifferentiation of mesen-
chymal stem cells (MSCs). The aim of the study was to investigate possible role of 
erythropoietin-pretreated mesenchymal stem cells (EPOa/MSCs) in burn wounds 
healing and to evaluate its in vivo differentiation into keratinocytes. 
Materials and methods: Forty rats were utilised in this study divided into four 
groups (n = 10 for each). Control group (I), burn group (II), burn + MSCs, group (III), 
burn + EPOa/MSCs. 1 × 106 cells were injected locally for each 1 cm2 of burn 
areas. Burn areas were followed-up morphologically. After 21 days of the exper-
iment, the rats were euthanised, skin specimens were assessed biochemically, 
histologically and immunohistochemically. 
Results: EPOa/MSCs enhanced significantly (p < 0.05) burn wound vimentin 
gene expression and level of interleukin (IL)-10 while decreased IL-1 and COX2 as 
compared to the burn group. Histologically, EPOa/MSCs improved epithelialisation 
despite stem cells’ differentiation into keratinocytes was rarely detected by PKH26 
red fluorescence. EPOa/MSCs promoted angiogenesis as detected by significant 
increase in VEGF and PDGF immunoexpression as compared to burn group.
Conclusions: EPOa/MSCs may improve burn wound healing, probably through 
anti-inflammatory, immunomodulatory and angiogenic action. However, in vivo 
transdifferentiation into keratinocytes was rarely detected. (Folia Morphol 2019; 
78, 4: 798–808)
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INTRODUCTION
Stem cells, by pronounced anti-inflammatory and 
angiogenic role, can improve wound healing through 
differentiation into skin cells. For so, stem cells have 
shown promising potential to treat burn wounds 
[21]. The unique abilities of mesenchymal stem cells 
(MSCs) to suppress the immune response, to secrete a 
large number of cytokines and chemokines, together 
with their potential for multilineage differentiation 
make them suitable for tissue regeneration through 
cell replacement and repair [15]. Mobilisation of 
bone marrow-derived mesenchymal stem cells (BM-
MSCs) regulated via CXCL12/CXCR4 signalling had 
promoted BM-MSCs migration into the burn wound 
margins enhancing re-epithelialisation [11]. Through 
reducing unhealed areas, and enhancement of the 
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dermal thickness, epidermal area as well as collagen 
content, allogeneic MSCs had been demonstrated to 
improve burn wound healing [5]. In the study of Liu 
et al. [19], a burn wound model was developed in 
pigs; tissue-engineered skin containing autologous 
MSCs was grafted on deep partial thickness wounds. 
They found that when stem cells were grafted onto 
the burn wounds, these substitutes had less contrac-
tion, more vascularisation, and improved epidermal 
formation. A lot of methods had been done to poten-
tiate the efficacy of stem cells in burn healing either 
by incorporation into tissue engineered scaffolds, by 
gene modification or by pretreatment with proliferat-
ing agents. It had been proved that MSCs-pretreated 
with platelets rich plasma (PRP) improved the histo-
pathology of burned skin 20 days post burn through 
upregulation of transforming growth factor beta 
(TGF-b), interleukin (IL)-10, angiopoietin-1, angiopoi-
etin-2 and vimentin while downregulation of tumour 
necrosis factor-alpha (TNF-a), matrix metalloprotein-
ase-1 and tissue inhibitor of metalloproteinase-2 [10]. 
Transplantation of genetically modified bone marrow 
MSCs with TGF-b3 in an animal model had remarkably 
improved wound healing and reduced skin scar tissue 
formation providing an alternative in the treatment of 
extensive scar tissue formation after soft tissue injury 
[17]. In addition to erythropoietin (EPOa) primary bio-
logical role in erythropoiesis, it acts as a paracrine and/ 
/or autocrine agent as a response to cellular stress [31]. 
Recently, recombinant human alpha-erythropoietin 
had been proved to accelerate cell proliferation and 
to promote endothelial transdifferentiation of human 
MSCs from the apical papilla (SCAP) [15]. Despite the 
promising results of MSCs in burn wound healing, 
the pathophysiological mechanisms mediating this 
action remains a challenge due to in vivo limitation 
of monitoring MSCs dynamics [23]. In this work, it 
was hypothesised that EPOa pretreated MSCs could 
improve burn wound healing. The aim of this work 
was to investigate this role and to evaluate its in vivo 
differentiation into keratinocytes.
MATERIALS AND METHODS
Animals
The experiment strictly adhered to all ethical guide-
lines regarding animal research and was approved by 
the Institutional Animal Care and Use Committee of 
Cairo University (CU-IACUC) number CU-III-F-47-18. 
Forty adult male albino rats weighing 200–250 g were 
used in this experiment. Animals were obtained from 
Animal House, Faculty of Medicine, Cairo University. 
They were housed under standard laboratory and en-
vironmental conditions, 20–23°C, 40–60% humidity, 
12 h light–dark cycle, with free access to food and 
water and fed ad libitum. 
Experimental design
Forty animals were utilised divided into four equal 
groups:
 — group I (n = 10): control group, skin was shaved 
and left for 3 weeks;
 — group II (n = 10): burn induction without mesen-
chymal cells injection;
 — group III (n = 10): burn induction + immediate 
local injection of MSCs 1 mL (1 × 106 cells) for 
each 1 cm2 of burn area;
 — group IV (n = 10): burn induction + immediate 
local injection of EPOa/MSCs 1 mL (1 × 106 cells) 
for each 1 cm2 of burn area.
Preparation of BM-MSCs from rats
The MSCs were obtained from the Biochemistry 
Department, Faculty of Medicine, Cairo University. 
They were derived from rats as previously described 
by Schrepfer et al. [26]. Ten rats were euthanised 
after administration of sodium pentobarbital intra-
peritoneally at a dose of 30 mg/kg. After cleaning 
from adherent tissues, the tips of femurs and tibiae 
were cut with a bone cutter. Bone marrow cells were 
flushed from the medullary cavities of the femurs and 
tibiae and disaggregated into a single-cell suspension 
by sequential passage through a 23-gauge needle. 
This single cell suspension was cultured in 15 mL of 
MSCs specific medium; minimum essential medium 
supplemented with 10% foetal bovine serum and 
penicillin/streptomycin, Gibco) in T-75 culture flasks 
at 37°C in 5% carbon dioxide incubator. Three to 
four days later, non-adherent cells were removed 
by changing the medium. After 10 days in culture, 
adherent cells formed homogenous fibroblast-like 
colonies. When MSCs become confluent (80–90%), 
adherent cells were passaged with trypsin (0.25%) by 
incubating for 10 min. Three passages were done to 
obtain the optimal number of MSCs before transplan-
tation. The de-adhered cells after trypsin treatment 
were collected in a 15 mL falcon tube and centrifuged 
at 480 g for 5 min and these cells were counted and 
tested for viability by trypan blue. 
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Flow cytometry analysis of cell surface markers
Immunophenotyping of BM-MSCs cell was exam-
ined by flow cytometry for CD34, CD29 and CD90 (BD 
Bioscience, USA). The cells were incubated at room 
temperature for 30 min with the previous monoclonal 
antibodies, labelled with fluorescein isothiocyanate 
(FITC) and analysed on a flow cytometer (FACS Caliber, 
BD Bioscience USA) [12, 27]. BM-MSCs cells exhibit-
ed negative reaction for the haematopoietic marker 
(CD34), while strong positive reaction for MSC specific 
markers including CD29 and CD90 (Fig. 1). 
MSCs treatment with erythropoietin
Mesenchymal stem cells growth was divided into 
two equal fractions, each fraction represented a group:
 — group 1: a control group of MSCs which were not 
treated with EPOa;
 — group 2: MSCs that were treated with EPOa 
(Eprex® injectable solution 10.000 IU/mL, Jans-
sen-Cilag Pty Ltd.). MSCs were seeded at 4 × 103 
cells/cm2 in tissue culture plates and incubated 
with the culture medium supplemented with EPOa 
(40 IU/mL) for 24 h [15]. 
The cells were examined for cell proliferation assay 
using the MTT (3-[4,5-dimethylthiazol-2-yl]-2.5-di-
phenyl tetrazolium bromide) cell proliferation kit 
(Trevigen Inc., Gaithersburg, MD, USA) as per man-
ufacturer’s protocol. Then MSCs were labelled with 
PKH26 red fluorescent linker dye supplied by Sigma 
(Saint Louis, Missouri, USA) for homing detection, 
and used for injection in the treated groups. MSCs 
1 × 106 in 1 mL of phosphate buffer saline, pH 7.4, 
were administered to the groups treated with cells 
for each 1 cm2 of the burn area.
Burn induction
Rats were anaesthetised with single intramus-
cular injection of 5% ketamine HCl (ketamine hy-
drochloride, Rotexmedica, Germany) (35.0 mg/kg) 
after injection of 2% xylazine HCl (VMD, Belgium) 
(5.0 mg/kg) via the quadriceps group of muscles [7]. 
The backs of the rats were shaved, prepared and skin 
burns were made by using a stainless steel tuning 
fork weighing 51 g with a rounded end (Fig. 2). 
After immersing in boiling (100°C) water for 5 min 
to induce full-thickness third-degree skin burns, the 
rounded end of tuning fork was applied without 
pressure for 15 s (proved histologically to produce 
full-thickness burn based on preliminary tests) on 
the back of the rats. This burn model was in close 
similarity to that described by Motamed et al. [22]. 
Daily rats’ observation for signs of discomfort had 
been performed and analgesics (Meloxicam, 20 mg/kg 
SC; Mobitil, MUP, Egypt) were given as needed for 
the first 5 days [30]. Following the burning, each 
animal was placed in a separate cage. As to pre-
Figure 1. Flow cytometry of mesenchymal stem cells (MSCs). 
The pink histograms represent antibody-labelled cells while the 
grey histograms show the profile of the isotype control. Bone 
marrow-derived MSCs cells exhibited negative reaction for CD34, 
while strong positive reaction for CD29 and CD90.
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vent burn wound infection, cefazolin 15 mg/kg sub-
cutaneous was given for the first 5 days [1, 19]. 
Skin burn areas were photographed at day 0, 7 and 
21 days from the experiment with measurement of 
the burn areas from scanned images using ImageJ 
Software (NIH, USA) starting within 2 h of burn inju-
ry for determination of original wound area (day 0) 
[30]. The rats were euthanised after 3 weeks from the 
experiment by intraperitoneal injection of pentobar-
bital 150 mg/kg. Skin burn specimens were obtained 
processed for biochemical, histological and immuno-
histochemical examination.
Biochemical analysis
Skin and burn wound specimens homogenates 
were used for estimation of COX2, IL-1, and IL-10 by 
ELISA supplied by MyBiosource, USA. Gene expression 
for vimentin was assessed by real-time polymerase 
chain reaction (RT-PCR). Total RNA was extracted from 
skin tissue homogenate using SV Total RNA Isolation 
System (Promega, Madison, WI, USA). Extracted RNA 
was quantified by spectrophotometer at 260 nm the 
total RNA was used for cDNA conversion using high 
capacity cDNA reverse transcription kit (#K1621, Fer-
mentas, USA). cDNA was generated from 10 μL of 
total RNA extracted with 3 μL antisense primer and 
1 μL superscript MMLV reverse transcriptase for 
60 min at 37°C. The relative abundance of mRNA species 
was assessed using the SYBR Green method on an 
ABI prism 7500 sequence detector system (Applied 
Biosystems, Foster City, CA). The forward primer for Vi-
mentin was 5’-GCACCCTGCAGTCATTCAGA-3’ with the 
Reverse primer: 5’-GCAAGGATTCCACTTTACGTTCA-3’) 
and Gene bank accession number (XM_ 007624597.2). 
All primer sets had a calculated annealing temperature 
of 60°C. Quantitative RT-PCR was performed in dupli-
cate in a 25 μL reaction volume consisting of 12.5 μL 
SYBR Green PCR Master mix, 1 μL of each primer and 
5 μL of cDNA. Amplification conditions were 2 min at 50° 
and 40 cycles of 15 s at 95°, 1 min at 60° and 1 min at 
72°C for the amplification step. Relative expression of 
vimentin was calculated using the comparative cycle 
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threshold method (DDCt). All values were normalised 
to the GAPDH genes and reported as fold change.
Histological examination
The skin specimens were prepared for histological 
staining using haematoxylin and eosin (H&E) as well 
as Masson’s trichrome stains.
Immunohistochemical examination
Deparaffinised sections were mounted on positively 
charged slides for staining with smooth muscle actin 
(SMA), vascular endothelial growth factor (VEGF) and 
platelets derived growth factor (PDGF). Heat-induced 
epitope retrieval (HIER) was done to the sections. Dako 
autostainer was used for immunohistochemistry [13, 
25]. Sections were EnVision Flex peroxidase blocked. 
Primary antibodies were VEGF (Santa Cruz, USA), 
a SMA (Dako, Denmark) and PDGF (Genetex, USA). 
Dako EnVision Flex/HRP had been used as secondary 
antibodies. Visualisation had been performed with En-
Vision FLEX DAB+ Chromogen. Prepared sections from 
H&E, Masson’s trichrome and immunohistochemical 
stains were photographed using a Canon digital camera 
(Canon, Japan) attached to the IBM computer system.
Histomorphometric analysis
The software Leica Quin 500, Germany, was used 
in performing image analysis for measuring the area 
per cent of positive immunohistochemical reactions 
of VEGF, PDGF and a SMA at a magnification ×400. 
ImageJ was used in counting the PKH26 fluorescent 
particles in different groups at the same magnifica-
tion. All data were expressed as mean ± standard 
deviation and processed for statistical analysis
Statistical analysis
All histomorphometric measurements, as well as 
the sizes of burn area were statistically analysed using 
the statistical package for the social sciences (SPSS) 
version 21.0 (IBM Corporation, Somers, NY, USA) 
statistical software. Statistical evaluation was done 
using analysis of variance (ANOVA) followed by post 
hoc Tukey test. Significance was considered when the 
p-value was less than 0.05.
RESULTS 
Proliferation assay test 
There was a significant increase (p < 0.05) in 
the per cent of cell proliferation of EPOa/MSCs as 
compared to the control group (MSCs only) (Fig. 2).
Clinical wound observations
Rats that received MSCs and EPOa/MSCs at day 
21 from burn induction showed better healing and 
epithelialisation as compared to those didn’t receive 
without a noticeable difference at day 7 from burn 
induction (Fig. 3). There was a significant decrease in 
burn area in rats that received MSCs and EPOa/MSCs 
only at day 21 from burn induction with a statistically 
nonsignificant decrease at day 7 from burn induction 
(Fig. 2). The rats treated with EPOa/MSCs exhibited 
significant decrease in burn area as compared to 
those treated with MSCs (Fig. 2). 
Biochemical results
Mesenchymal stem cells and EPOa/MSCs significant-
ly down-regulated IL-1B and COX2 while significantly 
up-regulated IL-10 in skin burn tissues of rats that re-
ceive them as compared to those that didn’t receive 
them (Table 1). EPOa/MSCs-treated group exhibited 
a significant decline in IL-1B and a significant increase 
in IL-10 as compared to MSCs-treated group (Table 1). 
Vimentin gene expression in burn group was significant-
ly decreased as compared to the control group (Fig. 2). 
MSCs and EPOa/MSCs significantly up-regulated vimen-
tin gene expression as compared to burn group (Fig. 2).
Histological results
On H&E staining (Fig. 4), control rats appeared 
with normal skin histology. The burn group showed 
granulation tissue with abundant fibrocytes. 
MSCs-treated group exhibited a partially healed 
epidermis with cellular inflammatory infiltrate. 
EPOa/MSCs-treated group showed apparently in-
tact epidermis with areas of hyperkeratinisation. On 
Masson’s trichrome staining (Fig. 4), control rats 
appeared with normal amount of collagen while 
burn group showed totally replaced skin by gran-
ulation tissue. MSCs group exhibited regenerating 
skin with modelling collagen fibres while EPOa/
MSCs-treated group appeared with well-modelled 
collagen fibres.
Immunohistochemical results
Immunohistochemical staining (Fig. 5) revealed 
burn group with decreased VEGF and PDGF immuno-
expression while increased a SMA immunoexpression. 
MSCs and EPOa/MSCs group exhibited decreased 
a SMA immunoexpression while increased dermal 
VEGF and PDGF immunoexpression as compared to 
burn group.
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Table 1. Inflammatory markers among different groups
Group COX2 [pg/mg protein] Intereukin-1B [pg/mg protein] Interleukin-10 [pg/mg protein]
Control 0043.1 ± 2.6 15.5 ± 2.2 139.5 ± 8.3
Burn 108.7 ± 7* 088.1 ± 5.9* 0074.1 ± 4.9*
Burn + MSCs 000072.5 ± 5.6*, @ 00059.1 ± 5.2*, @ 000104.1 ± 6.9*, @
Burn + EPOa/MSCs 000066.4 ± 3.3*, @ 0000044.6 ± 5.4*, @, # 00000117.9 ± 5.4*, @, #
MSCs — mesenchymal stem cells; EPOa/MSCs — erythropoietin-pretreated mesenchymal stem cells  
*statistically significant as compared to control; @statistically significant as compared to burn group; #statistically significant as compared to burn + MSCs
Figure 4. Burn group in haematoxylin and eosin (H&E) sections is showing granulation tissue with abundant fibrocytes (arrows). Stem 
cells­treated group is showing partially healed epidermis with cellular inflammatory infiltrate (arrow heads). The group that received erythro-
poietin-pretreated mesenchymal stem cells (EPOa/MSCs) is showing apparently intact epidermis with areas of hyperkeratinisation (incom-
plete arrow). By Masson’s trichrome stain, control group appeared with normal collagen fibres (curved arrows), while burn group is showing 
granulation tissue. Mesenchymal stem cells group is showing regenerating skin with modelling collagen fibres while EPOa/MSCs group appears 
with well­modelled collagen fibres.
Figure 3. The tuning fork used in burn induction. Rats that received mesenchymal stem cells and erythropoietin-pretreated mesenchymal 
stem cells (EPOa/MSCs) at day 21 showed a better healing and epithelialisation as compared to those that didn’t receive these treatments 
without a noticeable difference at day 7.
Tuning fork Burn  
day 0
Burn group 
day 7
Burn + MS 
day 7
Burn + EPOa/MSC 
day 7
Burn group 
day 21
Burn + MSC 
day 21
Burn + EPOa/MSC 
day 21
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PKH26 fluorescence results
PKH26 fluorescent detection of labelled stem cells 
(Fig. 6) revealed negative detection in control and 
burn groups while positive detection in MSCs-treated 
group and EPOa/MSCs-treated group. The detection 
was almost totally in the dermis with the absence of 
the PKH26 fluorescence in the epidermis.
Histomorphometric results (Fig. 7)
Area % of alpha-SMA positive reaction. It was 
significantly increased in burn group as compared to 
the control. Meanwhile, it was significantly decreased 
in burn + MSCs and burn + EPOa/MSCs groups as 
compared to the burn group with a more significant 
decrease in burn + EPOa/MSCs group as compared 
to burn + MSCs cells group. 
Area % of VEGF positive reaction. It was signif-
icantly decreased in burn group as compared to the 
control while significantly increased in MSCs treated 
and EPOa/MSCs-treated groups as compared to the 
burn group.
Area % of PDGF positive reaction. It was signif-
icantly decreased in burn group as compared to the 
control while significantly increased in MSCs-treat-
ed and EPOa/MSCs-treated groups as compared to 
the burn group with a more significant increase in 
EPOa/MSCs group as compared to MSCs-treated 
group.
Count of PKH26 fluorescent particles in dif-
ferent groups. It was significantly increased in the 
dermis of EPOa/MSCs group as compared to MSCs 
group. However, it was rarely detected in the epider-
mis of both MSCs and EPOa/MSCs groups.
DISCUSSION
A burn wound is a dynamic process that can deep-
en in time usually by infection, and thereby increase 
the total tissue damage and the risk of complications 
such as hypertrophic scarring [20]. Stem cell therapy 
had been shown as a promising modality for burn 
healing. A lot of methods had been done to po-
tentiate stem cell efficacy in burn healing either by 
incorporation into tissue engineered scaffolds or by 
pretreatment with proliferating agents. In the current 
work, pretreatment of mesenchymal stem cells by 
erythropoietin successfully enhanced their in-vitro 
proliferation, in-vivo burn healing as evidenced clin-
ically, histologically and histochemically. 
Burn area had significantly decreased in MSCs 
and EPOa/MSCs groups 21 days following injury as 
compared to the burn alone group of rats with no 
statistical significance 7 days from burn induction. 
Figure 5. Immunohistochemical stains. Burn group is showing decreased vascular endothelial growth factor (VEGF) and platelets derived 
growth factor (PDGF) immunoexpression while increased a staining with smooth muscle actin (SMA) immunoexpression (arrows). Mesen-
chymal stem cells and erythropoietin­pretreated mesenchymal stem cells (EPOa/MSCs) group are showing increased dermal VEGF and PDGF 
immunoexpression while decreased SMA immunoexpression as compared to burn group. 
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Figure 6. A, B. Control and burn groups respectively with negative PKH26 red fluorescence; C, D. Mesenchymal stem cells-treated group and 
erythropoietin­pretreated mesenchymal stem cells (EPOa/MSC) group respectively with positive fluorescence (white arrows). Note the lack of 
fluorescent dye in the epidermis (green arrow); PKH26 red fluorescence ×400.
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Partially agreeing with these results, no significant 
difference in time to wound epithelialisation was 
observed in adipose-derived stem cells treated versus 
untreated burn wounds after days 1, 4, 7, 14, 21 from 
burn induction despite favourable effect on collagen 
deposition and angiogenesis [2]. The smaller area of 
starting burn wound (1 cm2) in the latter study might 
be the cause of not detecting significant difference 
in wound closure; however, with larger starting burn 
wound (30% TBSA), the healing time of wounds in 
the burn transplanted human umbilical cord mes-
enchymal cells (hUC-MSCs) group was significantly 
shorter than that in the burn group [18]. It has been 
reported that rats treated with MSCs after burn injury 
had a higher percentage of vital tissue at the injury 
site as well as fewer apoptotic cells and as compared 
to the control group [24]. Two distinct phenotypes of 
MSCs were involved in the wound healing process: 
the pro-inflammatory M1 and the anti-inflammatory 
M2 [33]. MSC role in the control of cell migration, 
cytokine secretion and extracorporeal matrix dep-
osition is the result of the switching between both 
phenotypes which is mediated by different toll-like 
receptors (TLRs), specifically, stimulation of TLR3 and 
TLR4 switches the cell between an anti-inflammatory 
and pro-inflammatory phenotype, respectively [32].
Down-regulation of inflammatory markers COX2 
and IL-1B and up-regulation of anti-inflammatory 
marker IL-10 in the skin tissues burn of EPOa/MSCs 
group in the present work might clarify the possible 
mediating mechanism of these MSCs in burn healing. 
Similarly, there was a local increase in anti-inflamma-
tory cytokines IL-10 and TNF stimulated gene 6 (TSG-6) 
and decrease in the number of inflammatory cells and 
pro-inflammatory cytokines (IL-1, IL-6 and TNF-a) at 
the burn injury site following an intravenous injection 
of human umbilical cord MSCs [18]. Concordantly, 
it had been demonstrated that at early time points 
post-burn, rats treated with MSCs have decreased 
circulating levels of TNF-a, IL-6, white blood cells and 
C-reactive protein as compared to the control group 
[35]. In addition, MSCs have also demonstrated the 
ability to attenuate T cell activation and proliferation, 
decrease cytotoxic T cells, and increase immunosup-
pressive regulatory T cells [8]. Also, murine MSCs were 
injected intradermally in a rat burn model resulting in 
an increase in anti-inflammatory cytokines TGF-b and 
IL-10 in the blood and reduction of CD4+ and CD8+ 
cells in the spleen as compared to control PBS-treated 
rats [3]. MSCs had been shown to possess a paracrine 
action by secretion of “secretomes” or extracellular 
vesicles [6]. These secretomes can cause profound 
immunomodulatory effects when studied in vitro 
experiments by downregulating IL-6 and nitric oxide 
synthase, promoting M1 (pro-inflammatory) to M2 
(anti-inflammatory) polarisation of macrophages, in-
crease IL-10 concentrations, and increase adenosine 
triphosphate [6].
Vimentin gene expression was significantly in-
creased burn + MSCs or burn + EPOa/MSCs groups 
as compared to the burn group. In accordance, MSCs 
and PRP pretreated MSCs had been reported to 
up-regulate vimentin gene expression in burn wounds 
[10]. Vimentin is considered as type III intermedi-
ate filament that acts as a signal integrator during 
wound healing, orchestrating the healing process by 
controlling fibroblast proliferation, TGF-b secretion, 
collagen accumulation, and epithelial–mesenchymal 
transition processing [4]. 
Keratinocytes differentiation of MSCs either alone 
or EPOa/MSCs into keratinocytes or other epidermal 
cells was rarely detected in this work by PKH26 flu-
orescence. Supporting these results, a comparative 
study between allogeneic MSCs and culture modified 
monocytes in burn healing had detected that the 
majority of the MSCs were in the dermis not the 
epidermis and there was rare evidence of MSC dif-
ferentiation as seen by co-localisation of MSC with 
keratin 14 which was not observed in culture modified 
monocytes [5]. In addition, green fluorescence pro-
tein (GFP)-labelled hUC-MSCs injected IV 3 days after 
burn had been observed to mainly concentrate in the 
wound edge and wound base on weeks 2 and 3 after 
hUC-MSCs transplantation [18]. Contradictory to the 
present work, IV stem cells injection in burned rats 
followed by tracking of them in lesions immunohisto-
chemically by GFP, had resulted in strong GFP-positive 
staining in the epidermal region [23]. But this tracking 
was done early after burn induction and no actual 
epidermis consisting of keratinocytes appeared in the 
figures related but granulation tissue instead. Another 
contradictory research also reported localisation of 
IV injected stem cells in the epidermis and hair follicles 
in post burn-injured lesions [11]. Wound site levels of 
CXCL12 and CXCR4 had been increased in stem cells 
injected mice in the latter research and mobilisation 
of MSCs to the wound site had been significantly 
reduced by pre-treatment of the MSCs with a CXCR4 
antagonist thus affecting wound closure [11]. Even 
though, Recell® spray-on system in which a small 
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sample of the patient’s own skin is immersed in the 
enzyme solution in the RECELL system, which sep-
arates the skin cells to produce Spray-On Skin Cells 
in as little as 30 min with resultant of a suspension 
including keratinocytes, fibroblasts, and melanocytes, 
which are involved in wound healing. This Food and 
Drug Association approved alternative to traditional 
epidermal skin grafts (STSG) has been compared in 
a controlled randomised trial to meshed STSG for 
deep partial thickness burns with no statistically 
significant reduction in re-epithelisation time [9]. 
Another similar study have been conducted but was 
underpowered (sample size of 10) [28] and results of 
a larger trial are awaited. Nevertheless, it might be 
suggested that transplanted stem cells could stim-
ulate the naturally present skin stem cells to dif-
ferentiate into keratinocytes and other epidermal 
cells, further researches are needed to point out the 
mediating mechanisms.
VEGF and PDGF immunoexpression in the MSCs 
and EPOa/MSCs groups was significantly increased as 
compared to burn group in the present work. This 
confirms the angiogenic role of MSC in burn healing. 
Agreeing to these results, it was reported that Western 
blot analysis for TGF-b1 and VEGF performed in the 
burn injury lesions of mice that received MSCs/Fluc 
was higher than those of mice that did not receive 
[23]. Also, PDGF immunoexpression had been report-
ed to be up-regulated in MSCs and PRP-pretreated 
MSCs rats’ burn lesions as compared to those didn’t 
receive [10]. PDGF and TGF-b had been reported to 
participate in the stabilisation process of the newly 
formed vessels in wound healing by the recruitment 
of pericytes and smooth muscle cells and by the 
deposition of connective tissue. PDGF recruits smooth 
muscle cells and TGF-b suppresses endothelial prolif-
eration and migration, and enhances the production 
of extracorporeal matrix proteins [16].  
a SMA immunoexpression in MSCs and EPOa/ 
/MSCs groups was significantly decreased as com-
pared to burn group, this might confirm their favour-
able role in decreasing post healing scar formation. 
Contradictory to these results, it was reported that 
RT-PCR levels of mouse a SMA were elevated in both 
adipose-derived stem cells (ASC)-treated and control 
burns compared to unwounded skin with no signif-
icant difference in relative expression of a SMA was 
observed between ASC-treated and control groups 
suggesting that contraction of these wounds is similar 
between the two latter groups [2]. a SMA immuno-
expression results of the current study ascertained 
the EPOa/MSCs role in wound contraction. It was 
reported that fibroblasts enter the wound from the 
edges and migrate toward the centre in response to 
cytokines and growth factors. Some of these cells 
may differentiate into cells called myofibroblasts, 
which contain SMA and have increased contractile 
activity, and serve to close the wound by pulling its 
margins toward the centre [16]. Activated fibroblasts 
and myo fibroblasts also increase their synthetic ac-
tivity and produce connective tissue proteins, mainly 
collagen, which is the major component of the fully 
developed scar [16]. A number of studies had declared 
that through reducing expression of myofibroblast 
marker and the down-regulation of collagen I synthe-
sis, BM-MSCs had succeeded in reducing hypertrophic 
scarring [29, 34, 35].
EPOa/MSCs-treated rats showed more favourable 
biochemical, histological and immunohistochemical 
results as compared to MSCs-treated rats in the cur-
rent work, this might elucidate the stem cells prolif-
erating role of erythropoietin in vivo in addition to its 
in vitro proliferating role. Supporting these results, 
recombinant human-alpha erythropoietin (rhEPOa) 
had been proved to accelerate in vitro cell prolifera-
tion and to promote endothelial transdifferentiation 
of human MSCs from the apical papilla (SCAP) [15]. 
Erythropoietin also recently had been proved to be 
antifibrotic, protect rats against spongiofibrosis and 
improve urethral wound healing in a rat model of 
urethral injury [14]. However, the exact mechanism 
by which EPOa enhanced stem cells proliferation is 
still unclear and further researches are warranted.
CONCLUSIONS
EPOa/MSCs might improve burn wound healing 
probably through anti-inflammatory, immunomodu-
latory and angiogenic action. However, in vivo trans-
differentiation into keratinocytes had been rarely 
detected. 
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